Loading…
CALCIUM CHLORIDE is a brand name for Calcium Chloride, supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: 08/2025 4 DOSAGE AND ADMINISTRATION 02/2026 7 WARNINGS AND PRECAUTIONS 02/2026 Table of Contents Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 Table…
Verbatim from this product's HC label. Tap a section to expand.
02/2026 7 WARNINGS AND PRECAUTIONS 02/2026 Table of Contents Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ............................................................................................
2 Table of Contents ................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................
4 1 Indications .................................................................................................................. 4 2 Contraindications ........................................................................................................
4 4. Dosage and Administration ......................................................................................... 5 5. Overdose.....................................................................................................................
6 6. Dosage Forms, Strengths, Composition, and Packaging ............................................... 6 7. Warnings and Precautions........................................................................................... 9 8. Adverse Reactions .......................................................................................................
10 9. Drug Interactions ...................................................................................................... 12 10. Clinical Pharmacology ...............................................................................................
12 11. Storage, Stability and Disposal .................................................................................. 13 12. Special Handling Instructions ....................................................................................
13 PART II: SCIENTIFIC INFORMATION .............................................. Error! Bookmark not defined. 13. Pharmaceutical Information...................................................................................... 14 14. Clinical Trials .............................................................................................................
14 15. Microbiology ............................................................................................................. 15 16. Non-Clinical Toxicology […]
). For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764- 7669). 6. Dosage Forms, Strengths, Composition, and Packaging Table 1 – Dosage Forms, Strengths, and Composition Route of Administration Dosage Form/ Strength/Composition Non-Medicinal Ingredients Intravenous or intraventricular cavity injection 10 mL Calcium Chloride solution in a pre-filled, single use syringe (see Table 2 Dosage Forms) / 100 mg/mL / Calcium Chloride Dihydrate Hydrochloric Acid and/or Sodium Hydroxide for pH adjustment, Water for Injection USP Calcium Chloride Injection USP is supplied in single-use containers as follows: Table 2 – Dosage Forms & Packaging Container Volume Needle LifeShield® Abboject® Syringe1 10 mL 20-gauge Pre-filled Abboject® Syringe2 10 mL 20-gauge Pre-filled Ansyr® Syringe3 10 mL Needle-free, with luer lock adapter 1: LifeShield® Abboject® Syringe: Flexible and reliable, the ready-to-use LifeShield® Abboject® syringe minimizes errors and protects caregivers and patients alike.
It can be used for needle-free or shrouded Calcium Chloride Injection USP Page 7 of 18 Protected B / Protégé B needle access. The design features two pieces - a calibrated glass drug vial and a matching plastic syringe barrel with integral injector needle.
Medication, fluid path, and needle are sterile and nonpyrogenic if caps and needle cover are undisturbed and package intact. 2.
Abboject® Syringe:
Flexible and reliable, the ready-to-use Abboject® syringe minimizes errors and protects caregivers and patients alike. It can be used for needle-free access. The design features two pieces - a calibrated glass drug vial and a matching plastic luer lock syringe barrel.
Medication, fluid path, and needle are sterile and nonpyrogenic if caps and luer end cover are undisturbed and package intact. 3: Ansyr® Syringe: The Ansyr® syringe is a proprietary delivery option offering one-piece, polypropylene plastic construction with a needle-free male luer lock adapter.
02/2026 Table of Contents Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ............................................................................................
2 Table of Contents ................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................
4 1 Indications .................................................................................................................. 4 2 Contraindications ........................................................................................................
4 4. Dosage and Administration ......................................................................................... 5 5. Overdose.....................................................................................................................
6 6. Dosage Forms, Strengths, Composition, and Packaging ............................................... 6 7. Warnings and Precautions........................................................................................... 9 8. Adverse Reactions .......................................................................................................
10 9. Drug Interactions ...................................................................................................... 12 10. Clinical Pharmacology ...............................................................................................
12 11. Storage, Stability and Disposal .................................................................................. 13 12. Special Handling Instructions ....................................................................................
). . Calcium Chloride Injection and ceftriaxone intravenous solutions may be administered sequentially one after another if infusion lines at different sites are used, or if the infusion lines are replaced or infusion lines are thoroughly flushed between infusions with physiological salt solution to avoid precipitation.
Aluminum Toxicity Calcium Chloride Injection contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Research indicates that patients with impaired kidney function, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day can accumulate aluminum at levels associated with central nervous system and bone toxicities.
Tissue loading may occur at even lower amounts of aluminum. Exposure to aluminum from Calcium Chloride Injection at the recommended dose is not more than 10 mcg. When prescribing Calcium Chloride Injection in patients receiving parenteral nutrition solutions, limit the total daily patient exposure to aluminum to no more than 5 mcg/kg/day.
Hypotension, Bradycardia, Arrhythmias and Syncope with Rapid Administration Rapid injection of Calcium Chloride Injection may cause vasodilation, decreased blood pressure, bradycardia, arrhythmias, syncope, and cardiac arrest. It is particularly important to prevent a high concentration of calcium from reaching the heart because of the danger of cardiac syncope.
Too rapid an injection exceeding 1 mL/min may lead to hypotension and cardiac syncope (see
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Calcium Chloride in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Ansyr® syringes are available prefilled with a wide range of emergency medications. Graduated markings on the syringe barrel conform to ISO standards and clearly show any drug remaining. Medication and fluid path are sterile and nonpyrogenic if protective cover is undisturbed and package intact.
7. Warnings and Precautions General Risk of Ceftriaxone-Calcium Precipitation Do not mix or administer Calcium Chloride Injection simultaneously with ceftriaxone, even if using different infusion lines or different infusion sites as it can lead to precipitation of ceftriaxone-calcium (see2 CONTRAINDICATIONS).
. Calcium Chloride Injection and ceftriaxone intravenous solutions may be administered sequentially one after another if infusion lines at different sites are used, or if the infusion lines are replaced or infusion lines are thoroughly flushed between infusions with physiological salt solution to avoid precipitation.
Aluminum Toxicity Calcium Chloride Injection contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Research indicates that patients with impaired kidney function, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day can accumulate aluminum at levels associated with central nervous system and bone toxicities.
Tissue loading may occur at even lower amounts of aluminum. Exposure to aluminum from Calcium Chloride Injection at the recommended dose is not more than 10 mcg. When prescribing Calcium Chloride Injection in patients receiving parenteral nutrition solutions, limit the total daily patient exposure to aluminum to no more than 5 mcg/kg/day.
Hypotension, Bradycardia, Arrhythmias and Syncope with Rapid Administration Rapid injection of Calcium Chloride Injection may cause vasodilation, decreased blood pressure, bradycardia, arrhythmias, syncope, and cardiac arrest. It is particularly important to prevent a high concentration of calcium from reaching the heart because of the danger of cardiac syncope.
Too rapid an injection exceeding 1 mL/min may lead to hypotension and cardiac syncope (see 4 DOSAGE AND ADMINISTRATION). If injected into the ventricular cavity in cardiac resuscitation, it must not be injected into the myocardial tissue.
Arrhythmias with Concomitant Digoxin Use Calcium Chloride Injection USP Page 8 of 18 Protected B / Protégé B Arrhythmias may occur if Calcium Chloride Injection and digoxin are administered together. Hypercalcemia resulting from an overdose of Calcium Chloride Injection increases the risk of digoxin toxicity.
Avoid the use of Calcium Chloride Injection in patients receiving digoxin. If concomitant therapy is necessary, closely monitor ECG and calcium levels (see 9. 4 DRUG-DRUG INTERACTIONS). Tissue Necrosis and Calcinosis Administration of Calcium Chloride Injection in patients with local trauma may result in calcinosis cutis due to transient increase in local calcium concentration.
Calcinosis cutis can occur with or without extravasation of Calcium Chloride Injection, is characterized by abnormal dermal deposits of calcium salts, and clinically manifests as papules, plaques, or nodules that may be associated with erythema, swelling, or induration.
Tissue necrosis, ulceration, and secondary infection are the most serious complications. Calcium Chloride Injection USP is irritating to veins and must not be injected into tissues, since severe necrosis and sloughing may occur (see 2 CONTRAINDICATIONS).
4 Administration). Avoid extravasation or accidental injection into perivascular tissues. Should perivascular infiltration occur, immediately discontinue intravenous administration at that site and treat as needed. Local infiltration of […]
13 PART II: SCIENTIFIC INFORMATION .............................................. Error! Bookmark not defined. 13. Pharmaceutical Information...................................................................................... 14 14. Clinical Trials .............................................................................................................
14 15. Microbiology ............................................................................................................. 15 16. Non-Clinical Toxicology .............................................................................................
15 Patient Medication […]